readthroughSign in
Nov 12, 2026Quarterly update

Kodiak Sciences reports Phase 3 wins for Zenkuda and tabirafusp-ted, outlines BLA timelines

Kodiak said both Phase 3 DAYBREAK arms hit their primary endpoints, with a Zenkuda BLA planned by year end and KSI-101 topline data due in December.

Kodiak Sciences Inc. reported third quarter 2026 results and business updates on November 12, 2026. In the Phase 3 DAYBREAK study, Zenkuda (tarcocimab tedromer) met the primary endpoint with a p-value of 0.0007, showing vision gains and rapid, sustained retinal drying, with 54% of patients on 6-month dosing.1 The company said Zenkuda's safety profile was consistent with aflibercept.1 Kodiak stated the Phase 3 DAYBREAK study met its one-year primary endpoint of non-inferiority in best corrected visual acuity as of September 2026.1

In the same trial, tabirafusp-ted (KSI-501) met its vision primary endpoint (p-value of 0.0036) and an anatomical key secondary endpoint (p-value of <0.0001).1 The tabirafusp-ted program is moving forward in diabetic macular edema and is actively enrolling in the Phase 3 ALTO study.1

On regulatory plans, Kodiak said it intends to submit a Zenkuda multi-indication biologics license application in the fourth quarter of 2026, covering five positive Phase 3 studies in wet AMD, diabetic retinopathy and retinal vein occlusion.1 For KSI-101, the company said enrollment of the first 300-patient cohort in the PEAK trial for Pivotal Analysis 1 is complete, with topline results still expected in December 2026,1 and enrollment in the second pivotal cohort of 600 subjects across PEAK and PINNACLE is expected to finish in the fourth quarter of 2026, with topline data anticipated in the second quarter of 2027.1 If the PEAK data are positive, Kodiak said it plans to file a BLA for KSI-101 in the second quarter of 2027.1

On finances, Kodiak ended the third quarter with $88.7 million in cash and cash equivalents.1 After the quarter closed, the company raised $69 million in net proceeds from stock sales under its at-the-market equity program.1 Kodiak said its current cash is expected to support planned operations into 2027.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.